Skip to main content
Business

Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug

Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug

Feed excerpt — reported by MarketWatch

The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at MarketWatch →

Original Source

This article was syndicated from MarketWatch. All rights remain with the original publisher.